The follicle-stimulating hormone receptor: A novel target in genitourinary malignancies

Por Gartrell, Benjamin A., Tsao, Che-kai, Galsky, Matthew D.
Publicado no Urol Oncol (2012)

Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer

Por Tsao, Che-Kai, Seng, Sonia, Oh, William K., Galsky, Matthew D.
Publicado em 2011

Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies

Por Sivendran, Shanthi, Newport, Kristina, Horst, Michael, Albert, Adam, Galsky, Matthew D.
Publicado no Trials (2015)

Emerging personalized approaches for the management of advanced urothelial carcinoma

Por Tsao, Che-Kai, Gartrell, Benjamin A, Oh, William K, Galsky, Matthew D
Publicado no Expert Rev Anticancer Ther (2012)

Clinical trial awareness: Changes over time and sociodemographic disparities

Por Leiter, Amanda, Diefenbach, Michael A, Doucette, John, Oh, William K, Galsky, Matthew D
Publicado no Clin Trials (2015)

All roads lead to PP2A: Exploiting the therapeutic potential of this phosphatase

Por Sangodkar, Jaya, Farrington, Caroline, McClinch, Kimberly, Galsky, Matthew D., Kastrinsky, David B., Narla, Goutham
Publicado no FEBS J (2015)

Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer

Por Shevach, Jeffrey, Gallagher, Emily Jane, Kochukoshy, Teena, Gresia, Victoria, Brar, Manpreet, Galsky, Matthew D., Oh, William K.
Publicado no Front Oncol (2015)

Toxicities Following Treatment with Bisphosphonates and Receptor Activator of Nuclear Factor-κB Ligand Inhibitors in Patients with Advanced Prostate Cancer

Por Gartrell, Benjamin A., Coleman, Robert E., Fizazi, Karim, Miller, Kurt, Saad, Fred, Sternberg, Cora N., Galsky, Matthew D.
Publicado no Eur Urol (2013)

The Relationship between Centralization of Care and Geographic Barriers to Cystectomy for Bladder Cancer

Por Casey, Martin F., Wisnivesky, Juan, Le, Valerie H., Sarpel, Umut, Stensland, Kristian D., Oh, William K., Galsky, Matthew D.
Publicado no Bl Cancer (2016)

A Phase II, single-arm study of nivolumab in patients with metastatic or unresectable urothelial cancer who have progressed following treatment with a platinum agent

Por Sharma, Padmanee, Grimm, Marc-Oliver, Galsky, Matthew D, Baron, Ari, Bracarda, Sergio, Siefker-Radtke, Arlene, Lambert, Alexandre, Azrilevich, Alex, Retz, Margitta
Publicado no J Immunother Cancer (2015)

Multicenter Phase 2 Trial of the Hsp-90 Inhibitor, IPI-504 (retaspimycin hydrochloride), in Patients with Castration-Resistant Prostate Cancer

Por Oh, William K, Galsky, Matthew D., Stadler, Walter M., Srinivas, Sandy, Chu, Franklin, Bubley, Glenn, Goddard, J, Dunbar, Joi, Ross, Robert W
Publicado em 2011

Survival of Patients with Stage IV Lung Cancer with Diabetes Treated with Metformin

Por Lin, Jenny J., Gallagher, Emily J., Sigel, Keith, Mhango, Grace, Galsky, Matthew D., Smith, Cardinale B., LeRoith, Derek, Wisnivesky, Juan P.
Publicado no Am J Respir Crit Care Med (2015)

Metabolic complications with the use of mTOR inhibitors for cancer therapy

Por Sivendran, Shanthi, Agarwal, Neeraj, Gartrell, Benjamin, Ying, Jian, Boucher, Kenneth M., Choueiri, Toni K., Sonpavde, Guru, Oh, William K., Galsky, Matthew D.
Publicado no Cancer Treat Rev (2013)

Biomarkers for bladder cancer management: present and future

Por Ye, Fei, Wang, Li, Castillo-Martin, Mireia, McBride, Russell, Galsky, Matthew D, Zhu, Jun, Boffetta, Paolo, Zhang, David Y, Cordon-Cardo, Carlos
Publicado no Am J Clin Exp Urol (2014)

Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis

Por Gartrell, Benjamin A., Ying, Jian, Sivendran, Shanthi, Boucher, Kenneth M., Choueiri, Toni K., Sonpavde, Guru, Oh, William K., Agarwal, Neeraj, Galsky, Matthew D.
Publicado no Target Oncol (2013)

Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma(1)

Por Leiter, Amanda, Doucette, John, Krege, Susan, Lin, Chia-Chi, Hahn, Noah, Ecke, Thorsten, Sonpavde, Guru, Bamias, Aristotle, Oh, William K., Galsky, Matthew D.
Publicado no Bladder Cancer (2016)

Genomic differences between black and white patients implicate a distinct immune response to papillary renal cell carcinoma

Por Paulucci, David J., Sfakianos, John P., Skanderup, Anders J., Kan, Kathleen, Tsao, Che-Kai, Galsky, Matthew D., Hakimi, A. Ari, Badani, Ketan K.
Publicado no Oncotarget (2016)

Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer

Por Yadav, Shalini Singh, Li, Jinyi, Stockert, Jennifer A., O'Connor, James, Herzog, Bryan, Elaiho, Cordelia, Galsky, Matthew D., Tewari, Ashutosh Kumar, Yadav, Kamlesh Kumar
Publicado no Oncotarget (2016)

Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors

Por Galsky, Matthew D., Posner, Marshall, Holcombe, Randall F, Lee, Karen M., Misiukiewicz, Krzysztof, Tsao, Che-Kai, Godbold, James, Soto, Rothschild, Gimpel-Tetra, Kiev, Lowe, Nancy, Oh, William K.
Publicado em 2014

Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement

Por Galsky, Matthew D., Stensland, Kristian, Sfakianos, John P., Mehrazin, Reza, Diefenbach, Michael, Mohamed, Nihal, Tsao, Che-Kai, Boffetta, Paolo, Wiklund, Peter, Oh, William K., Mazumdar, Madhu, Ferket, Bart
Publicado no J Clin Oncol (2016)